Aurobindo Pharma Limited (BOM:524804)
India · Delayed Price · Currency is INR 1,497.85
+54.80 (3.80%)
At close: Jun 19, 2026
Aurobindo Pharma Revenue
In the fiscal year ending March 31, 2026, Aurobindo Pharma had annual revenue of 336.53B INR with 6.08% growth. Aurobindo Pharma had revenue of 88.53B in the quarter ending March 31, 2026, with 5.62% growth.
Revenue
336.53B
Revenue Growth
+6.08%
P/S Ratio
2.55
Revenue / Employee
12.15M
Employees
27,707
Market Cap
858.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 336.53B | 19.29B | 6.08% |
| Mar 31, 2025 | 317.24B | 27.22B | 9.39% |
| Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
| Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
| Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 335.93B |
| Lupin | 279.58B |
| Torrent Pharmaceuticals | 139.80B |
| Jubilant Pharmova | 82.80B |
| Abbott India | 69.29B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
Aurobindo Pharma News
- 13 hours ago - Aurobindo gets US FTC nod to acquire Lannett Co for $250 million - The Times of India
- 20 hours ago - HSBC maintains Buy on Aurobindo Pharma, sees progress toward $2 billion US sales goal - Business Upturn
- 20 hours ago - Aurobindo Pharma USA receives FTC approval for $250 million acquisition of Lannett - Business Upturn
- 3 days ago - Aurobindo Pharma's subsidiary faces five observations following US FDA inspection - Business Upturn
- 3 days ago - Pharma sector stocks today, June 19: IPCA Labs up 2.54%, Aurobindo Pharma gains 0.93%, Orchid Pharma falls 1.97% - Business Upturn
- 3 days ago - Aurobindo Pharma receives US FTC approval for Lannett acquisition - Business Upturn
- 4 days ago - FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett - Reuters
- 5 days ago - Pharma sector stocks today, June 17: Aurobindo Pharma gains 2.26%, Panacea Biotech falls 1.80%, Cipla down 0.32% - Business Upturn